anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
Cognitive dysfunction has been accepted as a possible complication of type 2 diabetes (T2D), but few studies revealed the potential roles of Long non‑coding RNAs (lncRNAs) in cognitive dysfunction in T2D. The current research aims to demonstrate the specific expression patterns of lncRNA-mRNA in the hippocampi of T2D db/db mice exhibiting cognitive impairment. In this study, the results from behavioral tests showed that T2D db/db mice displayed short-term and spatial working memory deficits compared to db/m mice. Furthermore, western blot analysis demonstrated that compared with db/m mice, p-GSK3β (ser9) protein levels were markedly elevated in T2D db/db mice (P < 0.01). In addition, though not statistically significant, the ratio of p-Tau (Ser396) to Tau 46, α-Synuclein expression, and p-GSK3α (ser21) expression were also relatively higher in T2D db/db mice than in db/m mice. The microarray profiling revealed that 75 lncRNAs and 26 mRNAs were dysregulated in T2D db/db mice (> 2.0 fold change, P < 0.05). GO analysis demonstrated that the differentially expressed mRNAs participated in immune response, extracellular membrane-bounded organelle, and extracellular region. KEGG analysis revealed that the differentially expressed mRNAs were mainly involved in one carbon pool by folate, glyoxylate and dicarboxylate metabolism, autophagy, glycine, serine and threonine metabolism, and B cell receptor signaling pathway. A lncRNA‑mRNA coexpression network containing 71 lncRNAs and 26 mRNAs was built to investigate the interaction between lncRNA and mRNA. Collectively, these results revealed the differential hippocampal expression profiles of lncRNAs in T2D mice with cognitive dysfunction, and the findings from this study provide new clues for exploring the potential roles of lncRNAs in the pathogenesis of cognitive dysfunction in T2D.
A total of 50 CM patients requiring surgical decompression will be recruited. The inclusion criteria are a clinical diagnosis of CM including the signs of corticospinal lesions together with the appropriate radiographic findings. Patients with acute spinal cord injuries, prior spinal intervention or claustrophobia will be excluded.
PURPOSE:To provide the subject remover capable of suppressing the conspicuousness of pares of the skin owing to effectively removing the corneoplug formed in the pores, thus enabling the pores to be kept clean, also causing no skin injuries. CONSTITUTION:The objective remover contain, as active ingredient, a polymeric compound having salt-forming group selected from carboxyl group, sulfonate residue, sulfate residue, phosphate residue, nitrate residue, amino group and ammonium group (pref. 10000-3000000, esp. 100000-1000000 in molecular weight), e.g. polymethacryloyloxymethyl succinate, polymethacrylamidopropyl trimethylammonium chloride. This remover is coated or applied on the skin and dried, and the resulting film is then peeled off the skin, thus removing corneoplug. In case the salt-forming group has not been ionized, it is preferable that the group be ionized by neutralizing it with an acid or base.
AKI is a very common disease in the intensive care unit. However, despite advances in supportive care, patients with AKI carry a high mortality rate (50% to 70%). The established AKI affects nearly 5 percent of hospitalized persons and as many as 15 percent of critically ill patients. Currently, there are no FDA approved therapeutic agents for the treatment of AKI.

Retrospective studies suggest that the early initiation of renal replacement therapy (RRT) improves outcome. Many clinicians tend to take a "wait and see" approach because they do not want to dialyze a patient who is destined to recover renal function without the need for RRT. Therefore, it is vitally important to know early in the course which patients with AKI are likely to progress to RRT.
The invention relates to innovative solid pharmaceutical forms of ticagrelor, which are advantageous over the state of the art in the following points: All doses of the drug are produced following the same linear pharmaceutical composition. They can incorporate active substance characterized by a wide range of particle sizes not varying their pharmaceutical characteristics so that they can present considerable flexibility and optimal cost-effectiveness. In particular, they can incorporate coarse grains active substances not disturbing their in-vivo behavior what implies significant advantages in production processes. They can incorporate different active substance polymorphs not varying the bioavailability of the drug. They are produced through a simple production process where the final form is in the form of tablets, preferably coated tablets. They show optimal stability, satisfactory mechanical strength and flexibility of use.
Falls are one of the most common accidents among stroke patients. Stroke patients are more prone to falls than community-dwelling older adults because of their cumulative risk factors of falls such as cognitive impairment and motor dysfunction. Recent studies on falls in Taiwan have primarily focused on falls of community-dwelling older adults. Research focused on falls among stroke patients in Taiwan, however, is scarce. Studies reported by researchers in other countries have only investigated the incidence and causes of falls of patients staying in medical institutions up to three months post-stroke. Therefore, the incidence and immediate causes of falls remain unknown for post-hospital discharge stroke patients during their sub-acute and chronic stages. In addition, whether falls of stroke patients after hospital discharge could be predicted by their clinical manifestations during hospital stay also requires further investigation.
After mandatory predilatation, a self-expanding, conically shaped nickel-titanium AXXESS biolimus A9-eluting stent is placed at the level of the carina. The device is available in 3.0 and 3.5 mm calibre and 11 and 14 mm length. Depending on the lesion anatomy, additional Biomatrix™ Drug Eluting Coronary Stent Systems are placed distally if necessary. The procedure is completed with kissing balloon postdilatation using non-compliant balloons sized to the reference vessel diameter of the distal branches. Before this kissing balloon inflation, consecutive high pressure inflations should be performed in both branches.
The invention discloses an anticancer analgesic preparation and a preparation method thereof. The anticancer analgesic preparation is prepared from the following raw materials in percentage by weight: 50 to 70 percent of sanchi; 10 to 30 percent of cicada slough; and 10 to 30 percent of long-nosed pit viper. The anticancer analgesic preparation has the advantages of accurate dosage, little weight difference, and high bioavailability, and guarantees the dosage of the patient. The dose is small; the patient takes one bag each time; and the anticancer analgesic preparation is convenient for administration and carrying. The pills of the invention do not contain sugar; and compared with sugar coated tablets, sugary granules and oral liquid, the pills enlarge administration population and are suitable for sugar forbidden population such as diabetics, obesity patients, and the like. The anticancer analgesic preparation and the preparation method thereof have the advantages of simple equipment, convenient operation, little dust in the production process and small environmental pollution.
Risk Summary    
Available data from published literature and postmarketing experience with levocetirizine use in pregnant women are insufficient to identify any drug-associated risks of miscarriage, birth defects, or adverse maternal or fetal outcomes. In animal reproduction studies, there was no evidence of fetal harm with administration of levocetirizine by the oral route to pregnant rats and rabbits, during the period of organogenesis, at doses up to 390 times and 470 times, respectively, the maximum recommended human dose (MRHD) in adults. In rats treated during late gestation and the lactation period, cetirizine had no effects on pup development at oral doses up to approximately 60 times the MRHD in adults. In mice treated during late gestation and the lactation period, cetirizine administered by the oral route to the dams had no effects on pup development at a dose that was approximately 25 times the MRHD in adults; however, lower pup weight gain during lactation was observed at a dose that was 95 times the MRHD in adults [see Data].   
The estimated background risk of major birth defects and miscarriage for the indicated population is unknown. All pregnancies have a background risk of birth defect, loss, or other adverse outcomes. In the U.S. general population, the estimated background risks of major birth defects and miscarriage in clinically recognized pregnancies is 2% to 4% and 15% to 20%, respectively.   
Data   
Animal data   
In embryo-fetal development studies, pregnant rats received daily doses of levocetirizine up to 200 mg/kg/day from gestation days 6 to 15 and pregnant rabbits received daily doses of levocetirizine up to 120 mg/kg/day from gestation days 6 to 18. Levocetirizine produced no evidence of fetal harm in rats and rabbits at doses up to 390 and 470 times the MRHD, respectively (on a mg/m2 basis with maternal oral doses of 200 and 120 mg/kg/day in rats and rabbits, respectively).   
No prenatal and postnatal development (PPND) studies in animals have been conducted with levocetirizine. In a PPND study conducted in mice, cetirizine was administered at oral doses up to 96 mg/kg/day from gestation day 15 through lactation day 21. Cetirizine lowered pup body weight gain during lactation at an oral dose in dams that was approximately 95 times the MRHD (on a mg/m 2 basis with a maternal oral dose of 96 mg/kg/day); however, there were no effects on pup weight gain at an oral dose in dams that was approximately 25 times the MRHD (on a mg/m2 basis with a maternal oral dose of 24 mg/kg/day). In a PPND study conducted in rats, cetirizine was administered at oral doses up to 180 mg/kg/day from gestation day 17 to lactation day 22. Cetirizine did not have any adverse effects on rat dams or offspring development at doses up to approximately 60 times the MRHD (on a mg/m 2 basis with a maternal oral dose of 30 mg/kg/day). Cetirizine caused excessive maternal toxicity at an oral dose in dams that was approximately 350 times the MRHD (on a mg/m 2 basis with a maternal oral dose of 180 mg/kg/day).
The present invention discloses a traditional Chinese medicine preparation which is externally used for treating teenager congenital myopia, hereditary myopia, true myopia, pseudomyopia and amblyopia, and a preparing method thereof. The traditional Chinese medicine preparation of the present invention is applied to the relevant points of a patient by professional and functional staff who are specially trained and cooperates with the patient to carry out dialectical treatment under the action of electrotherapeutic apparatus to make the traditional Chinese medicine preparation infiltrate into the points to dredge the liver and alleviate mental depression, promote blood circulation to remove meridian obstruction, replenish vital essence to tonify kidneys, replenish optic nerve nutrition and improve circumocular microcirculation to realize that the eyesight gradually gets right to realize the goal of curing. The traditional Chinese medicine preparation which is externally used of the present invention is prepared form 20 kinds of traditional Chinese medicine of radix bupleuri, semen cassiae, muskone, sea-ear shell, radices pseudoginseng, chuanxiong rhizome, zedoray rhizome, safflower, peach seed, barbary wolfberry fruit, glossy privet fruit, platycodon root, chrysanthemum, rehmannia dride rhizome, prepared rhizome of rehmannia, angelica, jackinthepulpit tuber, cuttlebone, red peony root, excrementum vespertilii, etc. which are respectively processed and soaked in white spirit according to different weight part proportion. The present invention has the advantage of low cost and is suitable for being popularized and applied. The cure rate reaches 95% and the effective rate reaches 100%.
The invention provides an in vitro avascular human corneal equivalent that comprises immortalized human cell lines. As these corneal equivalents are in vitro models, they are maintained in an incubator throughout the testing period, thereby eliminating the problems and expense associated with animal care. The corneal equivalent is preferably surrounded by a matrix in which angiogenesis (formation of capillary-like structures) can occur in vitro. This surrounding matrix has the potentioal to play the role of a pseudo-sclera, allowing the in vitro assessment of the cornea's angiogenic reaction to any substance or injury. Furthermore, the model is capable of being produced easily, is physiologically functional and can give predictable and quantifiable results when submitted to various drugs, chemicals and/or physical trauma. Modifications can be made, such as the use of primary donor cells instead of cell lines; and the physical and chemical treatments of the matrix material to make the constructs suitable for use in transplantation.
Risk Summary

Contraceptive hormones and/or metabolites are present in human milk. CHCs can reduce milk production in breastfeeding females. This reduction can occur at any time but is less likely to occur once breastfeeding is well established. Advise the nursing female to use another method of contraception until she discontinues breastfeeding [see Dosage and Administration (2.2)]. 

Data

Human Data

No studies have been conducted of the use of ANNOVERA in breastfeeding females. Two studies have been conducted in breastfeeding females of segesterone acetate implants delivering lower levels of segesterone acetate than ANNOVERA. Maternal serum levels of up to 141 pg/mL were associated with infant exposure of up to 7 pg/mL. No safety signals in feeding, growth, and development were observed in the infants between the segesterone acetate implant group and the control group.
The invention relates to a polypeptide which is able to specifically react with the antibodies of patients infected with HCV, the peptide sequence of said polypeptide comprising at least one sequence chosen from among SEQ IDL NO: 1 or SEQ IDL NO:2, chosen from the sequences having the immunoreactive properties of SEQ ID NO: 1 or SEQ ID NO: 2, and exhibiting, when compared to SEQ ID NO: 1 or SEQ ID NO: 2, at least one substitution of an amino acid by an equivalent amino acid, the equivalent amino acids being chosen from the following groups: Group 1:alanine, proline, glycine. Group 2: aspartic acid, glutamic acid. Group 3: histidine, lysine, arginine. Group 4: asparagine, glutamine, serine, threonine. Group 5: phenylalanine, tyrosine, tryptophane. Group 6: isoleucine, leucine, valine, methionine, and/or structurally modified. The invention also relates to the use of the said polypeptide for the detection and quantification of anti-HCV antibodies or of NS3 proteins, in a biological sample, or to obtain anti-bodies.
A series of three sequential focus groups will be used to gather ADRD caregiver feedback about EnACT intervention techniques, including frequency, duration, delivery, feasibility, acceptability, and relevance of the intervention. Between focus groups, we will refine and edit the EnACT intervention in an iterative process. Intervention scenarios and activities will be chosen and refined as part of Aim 1 in preparation for testing feasibility and acceptability.
OBJECTIVE: Approximately 70%-80% of children born with myelomeningocele develop hydrocephalus and need CSF diversion, commonly a ventriculoperitoneal shunt (VPS) placement. The optimal timing of surgery is not known, but many centers delay VPS placement and perform it in a separate surgery to avoid shunt complications, mainly shunt contamination and infection. This systematic review and meta-analysis aimed to compare shunt-related complications between populations with VPS surgery performed either simultaneously with myelomeningocele closure or with delay.
METHODS: The authors searched MEDLINE (PubMed), Scopus, Web of Science, Cochrane Central Register of Controlled Trials, and Cochrane Database of Systematic Reviews databases on December 15, 2022, and November 11, 2023, using a predefined search strategy. Randomized and nonrandomized trials of neonates undergoing postnatal myelomeningocele closure and VPS placement before the age of 29 days were included. Cases with prenatal myelomeningocele closure and hydrocephalus treatment other than a VPS were excluded. All studies were screened and assessed by two independent reviewers. The authors performed a meta-analysis pooling risk ratios (RRs) with a 95% CI using the random-effects model. The quality of studies was assessed using the Newcastle-Ottawa Scale.
RESULTS: After screening and a full-text review of 2099 database search results, 12 studies with a total number of 4894 patients were included. All studies were nonrandomized studies. Only 2 studies were ranked as good quality on the Newcastle-Ottawa Scale. No statistically significant differences were found between simultaneous and delayed shunt insertion in terms of shunt infection (RR 0.77, 95% CI 0.41-1.42); shunt revision (RR 0.49, 95% CI 0.19-1.30); overall mortality (RR 0.87, 95% CI 0.09-8.57); wound CSF leak (RR 0.20, 95% CI 0.03-1.23); or myelomeningocele wound dehiscence (RR 0.52, 95% CI 0.07-3.71). In the subgroup analysis of studies conducted in high-income countries, simultaneous shunting was superior to delayed shunting concerning shunt infection (RR 0.49, 95% CI 0.31-0.78) and shunt revision (RR 0.30, 95% CI 0.09-0.95).
CONCLUSIONS: This systematic review and meta-analysis found no statistically significant differences in shunt-related complications between simultaneous and delayed VPS surgery in myelomeningocele-related hydrocephalus in neonates. The current literature does not support the common practice of delayed shunting or its alternative, simultaneous shunting.
HIV infection with no ARV drug exposure (Group 2) represents adults, 18 years of age and older, continuously enrolled for at least 12 months in the Integrated Health Care Information Services (IHCIS) National Managed Care Benchmarked Database, a health insurance claims database, during the interval between January 1, 1997 and March 31, 2008, and with continuous eligibility for pharmacy benefits. HIV exposure will be identified by ICD-9-CM code 042 or v08 in one or more diagnostic fields. This group will have no pharmacy dispensing for ARV drugs.
The one arm of the study will have a venous blood draw as part of the research. 1 EDTA tube of 5mL will be collected.
Using current guidelines based primarily on ejection fraction (EF), only one-quarter of patients receiving an implantable cardiac defibrillator (ICD) for the primary prevention of sudden cardiac arrest (SCA) require appropriate ICD therapy within 5 years. The NIH-sponsored PAREPET study (Prediction of ARrhythmic Events with Positron Emission Tomography, ClinicalTrials.gov, NCT01400334) identified four independent risk factors that predict SCA or ICD equivalent in patients with ischemic cardiomyopathy. Using retrospectively defined cut-points, the absence of these risk factors identified 38% of the cohort with a very low risk of SCA (\<1% per year). This rate is actually lower than the 1.5-2% annual rate of SCA among patients with coronary artery disease and mild left ventricular (LV) dysfunction, who are not considered candidates for a primary prevention ICD. This proposal will prospectively determine whether these risk factors can form the basis of a clinically applicable approach to identify a subgroup of patients who are candidates for an ICD, but are at low enough risk of SCA to have an ICD safely withheld. Our long-term goal is to develop better approaches to identify patients with coronary artery disease who are most likely to benefit from prevention of SCA with placement of an implantable defibrillator.
Travoprost is absorbed through the cornea and is hydrolyzed to the active free acid. Data from 4 multiple dose pharmacokinetic studies (totaling 107 subjects) have shown that plasma concentrations of the free acid are below 0.01 ng/mL (the quantitation limit of the assay) in two-thirds of the subjects. In those individuals with quantifiable plasma concentrations (N = 38), the mean plasma Cmax was 0.018 ± 0.007 ng/mL (ranged 0.01 to 0.052 ng/mL) and was reached within 30 minutes. From these studies, travoprost is estimated to have a plasma half-life of 45 minutes. There was no difference in plasma concentrations between Days 1 and 7, indicating steady-state was reached early and that there was no significant accumulation. 

Travoprost, an isopropyl ester prodrug, is hydrolyzed by esterases in the cornea to its biologically active free acid. Systemically, travoprost free acid is metabolized to inactive metabolites via beta-oxidation of the α (carboxylic acid) chain to give the 1,2-dinor and 1,2,3,4-tetranor analogs, via oxidation of the 15-hydroxyl moiety, as well as via reduction of the 13, 14 double bond. 

The elimination of travoprost free acid from plasma was rapid and levels were generally below the limit of quantification within one hour after dosing. The terminal elimination half-life of travoprost free acid was estimated from fourteen subjects and ranged from 17 minutes to 86 minutes with the mean half-life of 45 minutes. Less than 2% of the topical ocular dose of travoprost was excreted in the urine within 4 hours as the travoprost free acid.
NEW MATERIAL:A compound expressed by formula I (R<1> and R<2> represent H, lower alkoxyl, etc.; X represents hydroxyl and Y represents cyano, or X and Y are combined with each other to form -X-Y- nd represent -O-) or hydroquinone type compound thereof. USE:An antitumor agent. PREPARATION:DX-52-1 expressed by formula II is initially used as a raw mate rial compound, which is reacted with a demethylating agent (example; boron tribromide) in an inert solvent, such as methylene chloride. Then the reaction liquid is poured into an ice water and a water phase is separated and purified to afford a compound expressed by formula III. Subsequently the compound is oxidized with potassium nitrosodisulfonate in an inert solvent, such as THF, to provide a compound expressed by formula IV, which is further reacted with a compound expressed by the formula R<1>'H ( R<1> represents the same as R<1> excepting H) in an inert solvent in the presence of an oxidizing agent. The produced compound expressed by formula V is reacted with a compound expressed by the formula R<2>'H (R<2>' represents the same as R<2> excepting H).
The current study is designed to test the short-term effectiveness and tolerability of MBX-2044 in patients with type 2 diabetes who are currently being controlled with up to one or two non-TZD hypoglycemic agent(s) including sulfonylureas, meglitinides, metformin, α-glucosidase inhibitors or Byetta®. Eligible patients will be enrolled into one of the following treatment cohorts receiving either placebo or MBX-2044 at 1.5, 4.5, 15, 30, or 60 mg/day in a double-blinded study for a 14-day treatment period. Patients will be evaluated for adverse events and vital signs daily. All efficacy and laboratory safety measures will be assessed after 2 weeks. This study will provide important information regarding the glucose-lowering efficacy of MBX-2044 and the safety of MBX-2044 (especially weight gain and edema) in diabetics. It will also provide important information about the appropriate doses to be used in subsequent longer-term studies to evaluate the safety and efficacy of MBX-2044 alone and in combination with other anti-diabetic agents.
At baseline and at the end of the 4-week period, a FFQ, four 24h-recalls and a questionnaire on consumed fruit and vegetable variety will be administered. At the end of the intervention period they receive once a basket of free fruits and vegetables.